INSULIN ASPART

INSULIN ASPART
(in'su-lyn)
NovoLog
Classifications: hormone; antidiabetic agent; insulin, rapid-acting;
Therapeutic: antidiabetic
; insulin rapid-acting
Prototype: Insulin injection
Pregnancy Category: C

Availability

100 U/mL injection

Action

A recombinant insulin analog that is more rapidly absorbed than human insulin, with a more rapid onset and shorter duration than regular human insulin.

Therapeutic Effect

Provides better blood glucose control than regular human insulin when given before a meal.

Uses

Treatment of diabetes mellitus.

Contraindications

Systemic allergic reactions; history of allergic reactions to insulin; hypoglycemia; pregnancy (category C).

Cautious Use

Fever, hyperthyroidism, surgery or trauma; decreased insulin requirements due to diarrhea, nausea, or vomiting, malabsorption; renal or hepatic impairment, hypokalemia.

Route & Dosage

Diabetes
Adult: SC 0.25–0.7 units/kg/d injected 5–10 min before each meal

Administration

Subcutaneous
  • Note: Must give 5–10 min before a meal.
  • Draw up insulin aspart first when mixing with NPH insulin. Give injection immediately after it is mixed. Do not give NPH mixture by IV.
  • Store refrigerated at 2°–8° C (36°–46° F); may be stored at room temperature, 15°–30° C (59°–86° F) for up to 28 d. Do not expose to excessive heat or sunlight, and do not freeze.

Adverse Effects (≥1%)

Body as a Whole: Allergic reactions. Endocrine: Hypoglycemia, hypokalemia. Skin: Injection site reaction, lipodystrophy, pruritus, rash.

Interactions

Drug: oral antidiabetic agents, ace inhibitors, disopyramide, fluoxetine, mao inhibitors, propoxyphene, salicylates, sulfonamide antibiotics, octreotide may enhance hypoglycemia; corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, phenothiazines, thyroid hormones, estrogens, progestogens, isoniazid, somatropin my decrease hypoglycemic effects; beta-blockers, clonidine, lithium, alcohol may either potentiate or weaken effects of insulin; pentamidine may cause hypoglycemia followed by hyperglycemia. Herbal: Garlic, ginseng may potentiate hypoglycemic effects.

Pharmacokinetics

Absorption: Rapidly absorbed from SC injection site. Onset: 15 min. Peak: 1–3 h. Duration: 3–5 h. Distribution: Low protein binding. Metabolism: In liver with some metabolism in the kidneys. Half-Life: 81 min.

Nursing Implications

Assessment & Drug Effects

  • Monitor for S&S of hypoglycemia (see Appendix F). Initial hypoglycemic response begins within 15 min and peaks 45–90 min after injection.
  • Lab tests: Periodically monitor fasting blood glucose and HbA1C.
  • Withhold drug and notify physician if patient is hypokalemic.

Patient & Family Education

  • Do not inject into areas with redness, swelling, itching, or dimpling.
  • Ingest some form of sugar (e.g., orange juice, dissolved table sugar, honey) if symptoms of hypoglycemia develop, and seek medical assistance.
  • Check blood sugar as prescribed, especially postprandial values; notify physician of fasting blood glucose <80 and >120 mg/dL.
  • Notify the physician of any of the following: Fever, infection, trauma, diarrhea, nausea or vomiting. Dosage adjustment may be needed.
  • Do not take any other medication unless approved by the physician.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(615)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 05/23/2025 (0)
×
Wait 20 seconds...!!!